Showing results (1031-1040 of 6,669) with videos related to

Sort By:
Pageof 667
Annals of Hematology|November 10, 2019
Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective studyVanja Zeremski, Kathleen Jentsch-Ullrich, Christoph Kahl, et al.
Annals of Hematology|December 7, 2019
Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomasSeo-Yeon Ahn, Seung-Yeon Jung, Sung-Hoon Jung, et al.
Annals of Hematology|December 8, 2019
Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemiaRahul Kaundal, Prateek Bhatia, Arihant Jain, et al.
Annals of Hematology|December 8, 2019
Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patientsHugo J A Adams, Thomas C Kwee
Annals of Hematology|February 7, 2020
Updates on DNA methylation modifiers in acute myeloid leukemiaBruna Contieri, Bruno Kosa Lino Duarte, Mariana Lazarini
Annals of Hematology|March 7, 2020
How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic reviewUmut Yilmaz, Muhlis Cem Ar, Sinem Nihal Esatoglu, et al.
Annals of Hematology|February 21, 2020
Prevalence of pulmonary hypertension in myelofibrosisJuan Lopez-Mattei, Srdan Verstovsek, Bryan Fellman, et al.
Annals of Hematology|February 21, 2020
Genetic polymorphisms of HbE/beta thalassemia related to clinical presentation: implications for clinical diversityNurul Fatihah Azman, Wan Zaidah Abdullah, Sarifah Hanafi, et al.
Annals of Hematology|February 24, 2020
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcomeB Bouchacourt, M A Hospital, C Zemmour, et al.
Annals of Hematology|January 23, 2020
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclaxYu-Wen Wang, Cheng-Hong Tsai, Chien-Chin Lin, et al.
Pageof 667